HUTCHMED begins phase III trial of HMPL-760 for lymphoma in China
#HUTCHMED #HMPL-760 #phase III trial #lymphoma #China #clinical development #cancer treatment
📌 Key Takeaways
- HUTCHMED initiates a phase III clinical trial for HMPL-760 in China.
- The trial targets lymphoma, a type of blood cancer.
- This marks a significant step in the drug's development process.
- The study aims to evaluate the efficacy and safety of HMPL-760 in a larger patient group.
🏷️ Themes
Clinical Trials, Oncology
Entity Intersection Graph
No entity connections available yet for this article.